^
Association details:
| Biomarker: | STRN-ALK rearrangement |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells
Published date:
01/30/2021
Excerpt:
...we report genomic and functional precision oncology profiling on a rare case of a 5-year old patient diagnosed with wide-spread and aggressive MPeM, driven by STRN-ALK rearrangement….the patient was treated with the ALK inhibitor crizotinib in combination with conventional chemotherapy (cisplatin and gemcitabine). A complete disease remission was reached, lasting now for over 3 years.
Secondary therapy:
GC
DOI:
10.1016/j.tranon.2021.101027
Source:
Title:
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Published date:
01/30/2021
Excerpt:
FM-MPeM-01 PDCs were analyzed for the expression of STRN-ALK...FM-MPeM-01 PDCs were sensitive to ALK inhibitors, as expected. From eight ALK inhibitors included in the drug library, six displayed selective cancer cell-specific sensitivity, including all approved ALK inhibitors, with brigatinib, ensartinib and crizotinib exhibiting highest sensitivities...
DOI:
https://doi.org/10.1016/j.tranon.2021.101027
